APA (7th ed.) Citation

S, L., T, A., B, M., B, C., O, T., H, M., . . . P, F. (2012). Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood, 119(22), 5104. https://doi.org/10.1182/blood-2011-07-365437

Chicago Style (17th ed.) Citation

S, Lepretre, et al. "Excess Mortality After Treatment with Fludarabine and Cyclophosphamide in Combination with Alemtuzumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia in a Randomized Phase 3 Trial." Blood 119, no. 22 (2012): 5104. https://doi.org/10.1182/blood-2011-07-365437.

MLA (9th ed.) Citation

S, Lepretre, et al. "Excess Mortality After Treatment with Fludarabine and Cyclophosphamide in Combination with Alemtuzumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia in a Randomized Phase 3 Trial." Blood, vol. 119, no. 22, 2012, p. 5104, https://doi.org/10.1182/blood-2011-07-365437.